Scarica l'app Stockscreener
14.97
1.84%
0.27
Dopo l'orario di chiusura:
14.68
-0.29
-1.94%
Precedente Chiudi:
$14.70
Aprire:
$14.5
Volume 24 ore:
419.00K
Relative Volume:
0.45
Capitalizzazione di mercato:
$827.01M
Reddito:
$88.24M
Utile/perdita netta:
$-160.90M
Rapporto P/E:
-5.6189
EPS:
-2.6642
Flusso di cassa netto:
$-129.35M
1 W Prestazione:
+2.04%
1M Prestazione:
+45.91%
6M Prestazione:
+67.64%
1 anno Prestazione:
+126.48%
Intervallo 1D:
$14.33
$15.00
Intervallo di 1 settimana:
$13.66
$15.13
Portata 52W:
$6.4668
$16.93
4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile
Nome
4 D Molecular Therapeutics Inc
Settore
Industria
Telefono
(510) 505-2680
Indirizzo
5858 HORTON STREET #455, EMERYVILLE
Compare FDMT vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
FDMT
4 D Molecular Therapeutics Inc
|
14.97 | 889.43M | 88.24M | -160.90M | -129.35M | -2.6642 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-28 | Ripresa | Barclays | Overweight |
| 2025-11-07 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2025-01-13 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-11-21 | Iniziato | Morgan Stanley | Underweight |
| 2024-09-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2024-04-15 | Iniziato | Barclays | Overweight |
| 2024-02-07 | Ripresa | Goldman | Buy |
| 2023-10-26 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-10-18 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2023-07-05 | Iniziato | Chardan Capital Markets | Buy |
| 2023-01-30 | Iniziato | BMO Capital Markets | Outperform |
| 2022-11-18 | Iniziato | H.C. Wainwright | Buy |
| 2022-11-15 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-08-12 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-06-22 | Iniziato | Jefferies | Buy |
| 2022-01-04 | Iniziato | SVB Leerink | Outperform |
| 2021-01-05 | Iniziato | BofA Securities | Buy |
| 2021-01-05 | Iniziato | Evercore ISI | Outperform |
| 2021-01-05 | Iniziato | Goldman | Neutral |
Mostra tutto
4 D Molecular Therapeutics Inc Borsa (FDMT) Ultime notizie
4D Molecular Therapeutics (NASDAQ: FDMT) CEO sells 69K shares in preset plan - Stock Titan
4D Molecular Therapeutics (NASDAQ:FDMT) Trading Down 3.7%Here's What Happened - MarketBeat
4D (FDMT) Watch: Advances 13.86% to $16.76; Boundary Watch: Price Remains Between $15.92 Support and $17.60 Resistance in Latest TradingSMA Signal - vinanet.vn
David Kirn plans $1.16M 4D Molecular (NASDAQ: FDMT) stock sale - Stock Titan
HC Wainwright Has Bullish Forecast for FDMT FY2027 Earnings - MarketBeat
4D Molecular Therapeutics CLO Scott Bizily sells $39,567 in stock - Investing.com
146,185 Shares in 4D Molecular Therapeutics, Inc. $FDMT Bought by Perigon Wealth Management LLC - MarketBeat
4D Molecular Therapeutics CLO Scott Bizily sells $39,567 in stock By Investing.com - Investing.com Canada
4D Molecular Therapeutics (NASDAQ:FDMT) Sets New 12-Month HighTime to Buy? - MarketBeat
4D Molecular Therapeutics CLO Scott Bizily Executes Stock Option Exercises and Sales Under 10b5-1 Plan - Kalkine Media
Scott Bizily Sells 1,635 Shares of 4D Molecular Therapeutics (NASDAQ:FDMT) Stock - MarketBeat
4D Molecular Therapeutics (NASDAQ:FDMT) Insider Scott Bizily Sells 1,635 Shares of Stock - MarketBeat
4D Molecular Therapeutics (NASDAQ: FDMT) legal chief sells 3,270 shares - Stock Titan
Scott Bizily plans new 4D Molecular (NASDAQ: FDMT) sale after 10b5-1 stock trades - Stock Titan
4D Molecular Therapeutics (NASDAQ:FDMT) Shares Up 10%Time to Buy? - MarketBeat
Persistent Asset Partners Ltd Makes New $1.94 Million Investment in 4D Molecular Therapeutics, Inc. $FDMT - MarketBeat
Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Alto Neuroscience, Inc. (ANRO) and Irhythm Technologies (IRTC) - The Globe and Mail
4DMT Announces New Employment Inducement Grants - The Manila Times
H.C. Wainwright reiterates Buy on 4D Molecular stock, $36 target By Investing.com - Investing.com Nigeria
4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
4D Molecular Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Is 4D Molecular Therapeutics Inc (FDMT) Undervalued After Q2 Ear - GuruFocus
4D Molecular Therapeutics (NASDAQ:FDMT) Announces Quarterly Earnings Results - MarketBeat
FDMT (NASDAQ: FDMT) stockholder schedules 1,635-share sale after option exercise - Stock Titan
4D Molecular Therapeutics (FDMT) posts $141.7M first-half 2026 net loss - Stock Titan
4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones - The Manila Times
4D Molecular Therapeutics Inc (FDMT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Dimensional Fund Advisors LP Purchases 227,982 Shares of 4D Molecular Therapeutics, Inc. $FDMT - MarketBeat
4D Molecular Therapeutics (FDMT) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
4D Molecular Therapeutics Inc (FDMT) Stock News Today - TradingKey
4D Molecular Therapeutics Inc expected to post a loss of $1.02 a shareEarnings Preview - TradingView
4D Molecular Therapeutics Inc (FDMT) Stock Price, Trades & News - GuruFocus
4D Molecular Therapeutics, Inc. (FDMT) insider sells 26,842 shares under plan - Stock Titan
Ken Fisher's 4D Molecular Therapeutics Inc(FDMT) Holding History - GuruFocus
4D Molecular Therapeutics (FDMT) Insider David Kirn Sells 12,415 Shares - GuruFocus
FDMT (FDMT) insider plans 26,842-share Class A sale after sizable prior trades - Stock Titan
David Kirn Sells 12,415 Shares of 4D Molecular Therapeutics (NASDAQ:FDMT) Stock - MarketBeat
4D Molecular Therapeutics (FDMT) CEO sells 12,415 shares via 10b5-1 plan - Stock Titan
Enterprise value to revenue forward of 4D Molecular Therapeutics, Inc. – NASDAQ:FDMT - TradingView
Form 144 4D Molecular Therapeutics For: 4 August By Investing.com - Investing.com Nigeria
FDMT (FDMT) investor David Kirn plans Rule 144 sale of 12,415 shares - Stock Titan
Janus Henderson Group PLC Acquires 611,276 Shares of 4D Molecular Therapeutics, Inc. $FDMT - MarketBeat
4D Molecular Therapeutics (NASDAQ:FDMT) Rating Increased to Strong-Buy at Chardan Capital - MarketBeat
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
4D Molecular Therapeutics, Inc. Revenue Breakdown – NASDAQ:FDMT - TradingView
Exome Asset Management LLC Purchases New Position in 4D Molecular Therapeutics, Inc. $FDMT - MarketBeat
4D Molecular Therapeutics Inc (FDMT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
4D Molecular Therapeutics Inc (FDMT) Income Statement - tradingkey.com
4D Molecular Therapeutics Inc (FDMT) Valuation: PE, PB & Fair Value Analysis - TradingKey
FDMT|4D Molecular Therapeutics Inc|Price:10.380|Chg%:+0.310 - TradingKey
4D Molecular Therapeutics Inc (FDMT) Balance Sheet - TradingKey
4 D Molecular Therapeutics Inc Azioni (FDMT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4 D Molecular Therapeutics Inc Azioni (FDMT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Kirn David | See Remarks |
Aug 19 '26 |
Sale |
15.75 |
69,076 |
1,088,273 |
825,819 |
0.86%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):